Vosoritide – September 2022

Vosoritide: Powder for injection 0.4 mg with diluent, Powder for injection 0.56 mg with diluent, Powder for injection 1.2 mg with diluent; Voxzogo® - July 2022 – September 2022 – November 2022 PBAC meetings

Brand names:
- Voxzogo®
Pharmaceutical Company:
- BioMarin Pharmaceutical Australia Pty Ltd
Condition/Indication: Achondroplasia
Meeting Date: September 2022
Public Summary Document (PSD) September 2022 PBAC Meeting - (PDF 1.3MB)
Public Summary Document (PSD) September 2022 PBAC Meeting - (Word 475KB)

Related Public Summary Documents

Vosoritide – July 2022
Vosoritide – November 2022

Last updated

30 May 2025